TY - JOUR
T1 - Lifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies
T2 - A population-based study in Southeast Minnesota
AU - Camerucci, Emanuele
AU - Mullan, Aidan F.
AU - Bower, James H.
AU - Bharucha, Adil E.
AU - Turcano, Pierpaolo
AU - Stang, Cole D.
AU - Benarroch, Eduardo E.
AU - Boeve, Bradley F.
AU - Ahlskog, J. Eric
AU - Savica, Rodolfo
N1 - Funding Information:
The research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health (NIH) under award number R01 AG034676 and by the Mayo Foundation for Medical Education and Research . The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding organizations were not involved in the design and conduct of the study, data collection, management, analysis, interpretation, or preparation, review, and approval of the manuscript.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2023/2
Y1 - 2023/2
N2 - Introduction: Epidemiological studies show correlations between constipation and development of Parkinson's disease (PD); however, few studies have explored the association between constipation and dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and multiple system atrophy (MSA). We sought to explore the lifelong association of constipation and PD, DLB, PDD, and MSA (α-Synucleinopathies), compared to age- and sex-matched controls. Methods: Using the Rochester Epidemiology Project (REP), we established an incident cohort of clinically defined α-synucleinopathies. A movement-disorder specialist reviewed all medical charts to establish clinical diagnoses. Results: We identified 453 incident cases of clinically diagnosed α-synucleinopathies and an identical number of age- and sex-matched controls in Olmsted County (MN), 1991–2010. There were 303 cases of PD; 80, DLB; 54, PDD; and 16, MSA. Approximately 50% of α-synucleinopathies of all types reported constipation, compared to 27% in controls. The earliest pre-motor onset constipation was in DLB (median, 3.76 years prior to α-synucleinopathies motor-symptom onset); latest onset post-motor constipation was in PD (median, 5.15 years after motor-symptom onset). PD also had the highest longstanding constipation rate (18.2%). All α-synucleinopathies had higher odds of constipation compared to controls, except for MSA (p = 0.09), likely due to a limited sample size. Conclusion: PD, DLB, and PDD had higher odds of constipation compared to controls; PD had the most widespread onset of lifelong constipation, both longstanding and pre- or post-motor onset symptoms. Our results indicate that constipation rates do not differ among α-synucleinopathies but do differ in terms of temporal onset compared to disease onset.
AB - Introduction: Epidemiological studies show correlations between constipation and development of Parkinson's disease (PD); however, few studies have explored the association between constipation and dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and multiple system atrophy (MSA). We sought to explore the lifelong association of constipation and PD, DLB, PDD, and MSA (α-Synucleinopathies), compared to age- and sex-matched controls. Methods: Using the Rochester Epidemiology Project (REP), we established an incident cohort of clinically defined α-synucleinopathies. A movement-disorder specialist reviewed all medical charts to establish clinical diagnoses. Results: We identified 453 incident cases of clinically diagnosed α-synucleinopathies and an identical number of age- and sex-matched controls in Olmsted County (MN), 1991–2010. There were 303 cases of PD; 80, DLB; 54, PDD; and 16, MSA. Approximately 50% of α-synucleinopathies of all types reported constipation, compared to 27% in controls. The earliest pre-motor onset constipation was in DLB (median, 3.76 years prior to α-synucleinopathies motor-symptom onset); latest onset post-motor constipation was in PD (median, 5.15 years after motor-symptom onset). PD also had the highest longstanding constipation rate (18.2%). All α-synucleinopathies had higher odds of constipation compared to controls, except for MSA (p = 0.09), likely due to a limited sample size. Conclusion: PD, DLB, and PDD had higher odds of constipation compared to controls; PD had the most widespread onset of lifelong constipation, both longstanding and pre- or post-motor onset symptoms. Our results indicate that constipation rates do not differ among α-synucleinopathies but do differ in terms of temporal onset compared to disease onset.
UR - http://www.scopus.com/inward/record.url?scp=85146317418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146317418&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2022.105244
DO - 10.1016/j.parkreldis.2022.105244
M3 - Article
C2 - 36630736
AN - SCOPUS:85146317418
SN - 1353-8020
VL - 107
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
M1 - 105244
ER -